PolyActiva presents positive clinical trial results
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022
Positive Phase IIa results in glaucoma trial with low dose cohort
PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.
PolyActiva successfully completes initial clinical trial
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
PolyActiva completes recruitment in key Phase I
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
PolyActiva commences its first Phase
PolyActiva commences its first Phase I clinical trial.